Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the year which we’ve pulled together here. If you’ve missed any of it, now’s the perfect time to catch up.
Evaluate aficionados will not be surprised to see that our annual World Preview report features on the list. This wide-ranging report on the future of the pharma market features forecasts of the top drugs, companies, therapy areas and pipeline projects looking out to 2030. It also investigates the wider market environment, including regulatory changes, the potential impact of the patent cliff, and the state of dealmaking.
Speaking of dealmaking, our BD&L specialists have been busy this year, creating content to help players on both the buy-side and sell-side to strike effective deals. You’ll find a best-practice article on out-licensing in our Top 10, but you’ll also find loads more in our dedicated BD&L content hub.
It’s not surprising that artificial intelligence (AI) and machine learning (ML) feature in the Top 10. It’s one of several pieces of content from our forecasting experts who joined Evaluate as part of the acquisition of J+D Forecasting at the start of the year. All those content pieces provide fantastic guidance on building forecasting models to support successful commercial launches in big indications and rare diseases. Definitely content to check out if you’re tasked with bringing a new therapy to market in 2025.
What else features in the pharma market Top 10?
Our analysis of the obesity landscape is in the list, hardly surprising given its profile in the market at the moment. In related content, we also recently published a piece on the heating-up MASH pipeline.
We also delved into the world of CDMOs, reporting back on whether the move towards a “one stop shop” is really here to stay.
We’ve covered a lot of ground and I hope there’s something in this list that you’ll useful or interesting – ideally both! Next year, we’ll continue to use Evaluate data to create insightful biopharma reports that will help clarify some of the most complex areas of the pharmaceutical market. If there is anything you’d love us to investigate, drop us a note at [email protected] and we’ll see what we can do. And remember you can find analysis of the breaking news in the pharma market in Scrip.
In the meantime, thank you for reading, and you’ll find the full back catalogue of our reports here. Enjoy!
